BR100 Increased By (0.91%)
BR30 Increased By (1.03%)
KSE100 Increased By (0.95%)
KSE30 Increased By (1.02%)
AGHA 6.38 No Change ▼ 0.00 (0%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.60 Increased By ▲ 0.05 (0.08%)
BOP 31.46 Increased By ▲ 0.07 (0.22%)
CNERGY 11.78 Increased By ▲ 0.05 (0.43%)
CSIL 5.79 Decreased By ▼ -0.12 (-2.03%)
FCCL 61.90 Increased By ▲ 0.19 (0.31%)
FFL 14.86 Increased By ▲ 0.07 (0.47%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.35 Increased By ▲ 0.03 (0.47%)
KOSM 5.81 Decreased By ▼ -0.09 (-1.53%)
LOTCHEM 24.79 Increased By ▲ 0.10 (0.41%)
MLCF 106.01 Increased By ▲ 2.08 (2%)
NBP 174.50 Increased By ▲ 1.18 (0.68%)
NCPL 52.60 Increased By ▲ 0.77 (1.49%)
NPL 54.80 Increased By ▲ 0.77 (1.43%)
OGDC 319.00 Increased By ▲ 3.13 (0.99%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.81 Increased By ▲ 0.23 (0.65%)
PIBTL 14.24 Increased By ▲ 0.58 (4.25%)
PPL 229.99 Increased By ▲ 3.92 (1.73%)
PRL 81.40 Increased By ▲ 1.12 (1.4%)
PTC 46.80 Increased By ▲ 0.16 (0.34%)
SSGC 24.13 Increased By ▲ 0.31 (1.3%)
TBL 9.36 Increased By ▲ 0.12 (1.3%)
TELE 7.60 Increased By ▲ 0.05 (0.66%)
TPL 24.70 Increased By ▲ 0.16 (0.65%)
TPLP 12.94 Decreased By ▼ -0.05 (-0.38%)
TREET 26.50 Increased By ▲ 0.52 (2%)
TRG 53.75 Increased By ▲ 0.42 (0.79%)
World

WHO approves Bavarian Nordic’s mpox vaccine for adolescents

Published Updated
By

The World Health Organization said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8.

The WHO declared mpox a global public health emergency for the second time in two years in August after a new type of the virus spread from the Democratic Republic of Congo to its neighbours.

World better positioned against mpox than for Covid: vaccine alliance

The United Nations agency approved the use of the vaccine in September as the first shot against mpox in adults, making it easier for badly hit African countries to access the vaccine.

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

WHO’s latest decision comes after the EU approved the drug for the vaccine for adolescents in September.

Comments

Comments are closed for this article.